NanoVibronix 2025 Q2 Earnings Sharp Net Loss Increase Amid Narrowed EPS Loss

NanoVibronix reported its fiscal 2025 Q2 earnings on August 19, 2025. The results fell short of expectations, with a sharp increase in net loss despite an improvement in per-share loss. The company provided no specific guidance for the remainder of 2025 but emphasized disciplined spending and the pursuit of near-term clinical data to support investor confidence.

Revenue
Total revenue for NanoVibronix declined significantly by 39.5% in 2025 Q2, dropping to $494,000 compared to $817,000 in the same period a year earlier.

Earnings/Net Income
The company narrowed its per-share loss to $1.03 in 2025 Q2, an improvement of 96.2% from $27.18 per share in 2024 Q2. However, the net loss expanded to $-3.97 million, a 477.2% increase from the $-688,000 loss in the prior year, underscoring the negative net income performance.

Price Action
The stock price experienced significant volatility, with a 11.78% drop in the latest trading day and a 25.44% decline during the most recent full trading week, while it surged 448.51% month-to-date.

Post-Earnings Price Action Review
A strategy of buying NanoVibronix shares 30 days after the quarterly earnings report and holding for an additional 30 days resulted in a severe loss over the past three years. The approach yielded a return of -98.82%, vastly underperforming the benchmark by 151.92%. The strategy's Sharpe ratio of -0.45 highlights the high risk involved, and the maximum drawdown of 0% suggests it failed to mitigate losses during down markets.

CEO Commentary
NanoVibronix CEO David B. Bissell emphasized continued investment in research and development despite ongoing financial challenges. He noted the importance of clinical progress and strategic collaborations to drive long-term value, while maintaining disciplined capital allocation and operational efficiency. Bissell expressed cautious optimism about future milestones and potential partnerships.

Guidance
The CEO did not provide explicit quantitative guidance for the remainder of 2025 but indicated the company expects to maintain current spending levels while evaluating new funding opportunities. Forward-looking statements emphasized the need for disciplined capital use and the pursuit of near-term clinical data to support investor confidence.

Additional News
On June 10, 2025, the Zhejiang Water Resources Center issued a blue-level flood warning for the Hangzhou-Jiaxing-Huzhou plain. Due to concentrated rainfall, flood conditions were expected at the Jiaxing hydrological station between June 10 and 12, affecting Hangzhou, Jiaxing, and Huzhou. Authorities urged residents, construction sites, and vessels to remain cautious and take preventive measures to ensure safety.